Ipca Laboratories has made an open offer to buy a 26 per cent stake or 35.7 lakh shares of Krebs Biochemicals & Industries at Rs.54 a share. The open offer follows Ipca Labs subscribing to 23 lakh shares of Krebs Bio on a preferential basis, the company said in a notice to the stock exchanges. The transaction is subject to necessary approvals.
At the end of December, promoters hold 48.33 per cent stake in Krebs Biochemicals while institutions control just 1.36 per cent. Some 6,130 individual shareholders have 36.34 per cent stake in the company. Of them, just 24 high net worth shareholders control 12.14 per cent stake.
Ipca Labs posted a net profit of Rs.41.53 crore for the quarter ended December 2014 on revenues of Rs.740.65 crore, while Krebs Biochemicals has been making losses for successive quarters. On Friday, shares of Ipca Labs edged up 1.7 per cent at Rs.680.95 on the BSE, while Krebs’ shares climbed 10 per cent to close at Rs.68.95.
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…